Recent Mayo Clinic research supports the reliability of the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio for diagnosing Alzheimer's, according to a release. The test,...
Foresight Diagnostics announced a strategic, worldwide partnership with QIAGEN to develop and commercialize a kit-based version of Foresight’s CLARITY assay, with the goal...
To take the test online go HERE. For more information, visit the Continuing Education tab. LEARNING OBJECTIVES 1. Discuss current statistics of congenital cytomegalovirus (cCMV...
Randox Laboratories announced that the U.S. Food and Drug Administration (FDA) has approved the De Novo application for the company’s first Companion Diagnostic (CDx). The...
MD Anderson Cancer Center scientists discovered a new biomarker that can predict “survival outcomes for patients with advanced KRAS G12C-mutated non-small cell ...
Foresight Diagnostics, Inc. announced the presentation of independent validation data demonstrating the prognostic performance of its Foresight CLARITY MRD assay in patients with...
QIAGEN announced a new commercial partnership and co-marketing agreement with ID Solutions to expand the availability of dPCR assays for oncology research applications. ...
The global C-reactive protein (CRP) testing market, valued at USD 3.3 billion in 2024, is on a path of steady growth, with projections indicating a compound annual growth rate...
Fujirebio announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the first in vitro diagnostic device that tests blood to aid in diagnosing...
Roche announced that the U.S. Food and Drug Administration (FDA) has approved the VENTANA MET (SP44) RxDx Assay, the first companion diagnostic approved to aid in determining ...
National Institutes of Health (NIH) scientists have uncovered a possible breast cancer biomarker that could help distinguish high risk patients and lead to better prevention and...